During the final week of spring training, Ervin Santana was sitting in his SUV in the parking lot of a restaurant not far from Hammond Stadium in Fort Myers, Fla., talking with fans through Periscope, a popular video-streaming app.
He answered questions about his favorite stadiums and whether he's going to have a big year. Some fans just want a shout-out.
"They want to know and they ask questions," said Santana, an active social media member whose Twitter account has more than 150,000 followers, before the team left its spring camp.
On this day, there were no probing questions, particularly none about his performance-enhancing-drug-related suspension last year that delayed his Twins debut by 80 games and stunned the team just before the start of the regular season.
Once his season started on July 5, Santana became an indispensable part of the Twins rotation. He enters this season as their Opening Day starter — his first as a major leaguer — and de facto staff ace. It's the full season both the Twins and Santana envisioned when they signed a four-year, $55 million deal — the richest contract the team has bestowed upon a free-agent pitcher.
Six months of Santana, the Twins hope, makes them more of a playoff threat. He'll be facing the Baltimore Orioles on Monday in his Opening Day assignment.
"We brought him in two winters ago with the idea of him being a reliable guy who can give you innings and repeat almost every start," Twins manager Paul Molitor said. "It is good to know we have him from Day 1."
Forget the 'bad times'
Santana has been reluctant to delve into details about last year's suspension, the result of a positive test for Stanozolol, a drug on Major League Baseball's list of banned substances. The announcement came on April 3, 2015, days after Santana finished a strong spring training, going 3-1 with a 1.89 ERA. It came a three days before the season opener in Detroit.